Nothing Special   »   [go: up one dir, main page]

YU84703A - Oralni rastvor aripiprazola - Google Patents

Oralni rastvor aripiprazola

Info

Publication number
YU84703A
YU84703A YU84703A YUP84703A YU84703A YU 84703 A YU84703 A YU 84703A YU 84703 A YU84703 A YU 84703A YU P84703 A YUP84703 A YU P84703A YU 84703 A YU84703 A YU 84703A
Authority
YU
Yugoslavia
Prior art keywords
oral solution
aripiprazole
acid
aripiprazole oral
solution
Prior art date
Application number
YU84703A
Other languages
English (en)
Inventor
Prakash Parab
Joyce Chou
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU84703(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of YU84703A publication Critical patent/YU84703A/sh
Publication of RS52082B publication Critical patent/RS52082B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sadašnji pronalazak obezbeđuje farmaceutski rastvor pogodan za oralnu administraciju i uključuje aripiprazol, farmaceutski pogodni sistem rastvarača, jedno ili više sredstava za poboljšanje i/ili za maskiranje ukusa, i jedan ili više agenasa odabranih od grupe koja uključuje mlečnu kiselinu, sirćetnu kiselinu, vinsku kiselinu i limunsku kiselinu, pri čemu je pH navedenog rastvora između 2.5 i 4.5.[The present invention provides for a pharmaceutical solution suitable for oral administration comprising aripiprazole, a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents and one or more agents selected from the group consisting of lactic acid, acetic acid, tartaric acid and citric acid, wherein said solution has a pH from 2.5 to 4.5.
YU84703A 2001-04-25 2002-04-24 Oralni rastvor aripiprazola RS52082B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25

Publications (2)

Publication Number Publication Date
YU84703A true YU84703A (sh) 2006-08-17
RS52082B RS52082B (sr) 2012-06-30

Family

ID=23099862

Country Status (37)

Country Link
US (1) US6977257B2 (sh)
EP (2) EP2436384B2 (sh)
JP (1) JP4401077B2 (sh)
KR (1) KR100909329B1 (sh)
CN (1) CN1512884B (sh)
AR (1) AR033168A1 (sh)
AT (1) ATE537831T1 (sh)
AU (1) AU2002254722B2 (sh)
BG (1) BG66177B1 (sh)
BR (1) BR0208986A (sh)
CA (1) CA2445276C (sh)
CY (1) CY1112606T1 (sh)
CZ (1) CZ306181B6 (sh)
DK (1) DK1381367T3 (sh)
EE (1) EE05581B1 (sh)
ES (1) ES2377855T3 (sh)
GE (1) GEP20053602B (sh)
HK (2) HK1058316A1 (sh)
HR (1) HRP20030870B1 (sh)
HU (1) HU230456B1 (sh)
IL (2) IL158202A0 (sh)
IS (1) IS2863B (sh)
MX (1) MXPA03009728A (sh)
MY (1) MY129350A (sh)
NO (1) NO324606B1 (sh)
NZ (1) NZ528550A (sh)
PE (1) PE20021086A1 (sh)
PL (1) PL206882B1 (sh)
PT (1) PT1381367E (sh)
RS (1) RS52082B (sh)
RU (1) RU2295960C2 (sh)
SK (1) SK287948B6 (sh)
TW (1) TWI337865B (sh)
UA (1) UA76144C2 (sh)
UY (1) UY27273A1 (sh)
WO (1) WO2002085366A1 (sh)
ZA (1) ZA200307797B (sh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
GEP20063996B (en) * 2002-08-20 2006-12-11 Bristol Myers Squibb Co Aripiprazole complex formulation and use thereof
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
CA2552988A1 (en) * 2004-01-21 2005-08-04 Janssen Pharmaceutica Nv Mitratapide oral solution
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
PL1808165T3 (pl) * 2006-01-05 2009-09-30 Teva Pharma Suche formulacje aripiprazolu
DE602006004694D1 (de) * 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
WO2007144874A1 (en) 2006-06-12 2007-12-21 Hadasit Medical Research Services And Development Ltd. Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
PL2170279T3 (pl) 2007-07-31 2018-05-30 Otsuka Pharmaceutical Co., Ltd. Sposoby wytwarzania zawiesiny arypiprazolu i liofilizowanej formulacji
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
PA8855801A1 (es) 2008-12-23 2010-07-27 Sintesis de nucleosidos de purina
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
WO2010146872A1 (ja) * 2009-06-19 2010-12-23 株式会社メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
PL3156056T3 (pl) 2011-03-18 2024-04-29 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne zawierające estry sorbitanu
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
JP6034377B2 (ja) * 2011-06-27 2016-11-30 シャンハイ チョンシ ファーマシューティカル コーポレイション アリピプラゾール医薬製剤及びその調製方法
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
ES2765036T3 (es) 2012-03-19 2020-06-05 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden esteres de ácidos grasos
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2014002553A1 (ja) 2012-06-29 2014-01-03 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
WO2014052678A1 (en) * 2012-09-26 2014-04-03 Bristol-Myers Squibb Company Apixaban liquid formulations
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US20140107130A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals, LLC Oral Solution Formulations of Aripiprazole
EP2908859B1 (en) 2012-10-16 2017-05-17 Arven Ilac Sanayi ve Ticaret A.S. Aripiprazole formulations
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
MA39495A (fr) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Ltd Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) * 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) † 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) † 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) † 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (sh) 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
JP2001518879A (ja) * 1997-03-31 2001-10-16 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 薬剤化合物の向上した浸透性のための溶媒システム
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
BR9913432A (pt) * 1998-09-03 2001-10-09 Alcide Corp Germicidas tópicos resistentes ao congelamento e métodos a eles relacionados
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Also Published As

Publication number Publication date
DK1381367T3 (da) 2012-04-10
EP2436384B1 (en) 2015-06-10
SK12642003A3 (sk) 2004-07-07
EP2436384A3 (en) 2012-09-19
CZ20032821A3 (cs) 2004-09-15
IS6994A (is) 2003-10-14
HRP20030870B1 (en) 2011-10-31
GEP20053602B (en) 2005-08-10
RU2003132426A (ru) 2005-04-20
BG108216A (bg) 2004-12-30
NO20034705L (no) 2003-11-28
NO20034705D0 (no) 2003-10-21
EP1381367B1 (en) 2011-12-21
NZ528550A (en) 2005-03-24
HUP0303946A3 (en) 2005-06-28
EP1381367A1 (en) 2004-01-21
HK1168792A1 (en) 2013-01-11
CY1112606T1 (el) 2016-02-10
KR20030096332A (ko) 2003-12-24
SK287948B6 (sk) 2012-06-04
HK1058316A1 (en) 2004-05-14
CA2445276A1 (en) 2002-10-31
EE05581B1 (et) 2012-10-15
JP2004532225A (ja) 2004-10-21
HU230456B1 (hu) 2016-07-28
TWI337865B (en) 2011-03-01
EE200300523A (et) 2004-02-16
CN1512884B (zh) 2010-05-26
US20020193438A1 (en) 2002-12-19
MXPA03009728A (es) 2004-01-29
IS2863B (is) 2013-12-15
ATE537831T1 (de) 2012-01-15
AR033168A1 (es) 2003-12-03
IL158202A (en) 2008-04-13
MY129350A (en) 2007-03-30
JP4401077B2 (ja) 2010-01-20
UY27273A1 (es) 2002-11-29
UA76144C2 (uk) 2006-07-17
KR100909329B1 (ko) 2009-07-24
HUP0303946A2 (hu) 2004-04-28
CZ306181B6 (cs) 2016-09-14
BG66177B1 (bg) 2011-11-30
ZA200307797B (en) 2004-10-06
CN1512884A (zh) 2004-07-14
PE20021086A1 (es) 2002-12-14
PL364666A1 (en) 2004-12-13
PT1381367E (pt) 2012-03-01
PL206882B1 (pl) 2010-10-29
EP2436384B2 (en) 2018-05-23
US6977257B2 (en) 2005-12-20
RU2295960C2 (ru) 2007-03-27
WO2002085366A1 (en) 2002-10-31
EP1381367A4 (en) 2009-07-01
CA2445276C (en) 2009-10-13
EP2436384A2 (en) 2012-04-04
HRP20030870A2 (en) 2004-06-30
IL158202A0 (en) 2004-05-12
BR0208986A (pt) 2004-04-20
NO324606B1 (no) 2007-11-26
RS52082B (sr) 2012-06-30
ES2377855T3 (es) 2012-04-02
AU2002254722B2 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
YU84703A (sh) Oralni rastvor aripiprazola
HK1047575A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containingthe same.
EG24228A (en) Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
GB9914486D0 (en) Medicaments
GEP20063895B (en) Platinum derivative pharmaceutical formulations
EP1040823A3 (en) Stable foam compositions
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MA26995A1 (fr) Derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
MXPA03010761A (es) Combinaciones farmaceuticas.
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
GB9907571D0 (en) Compounds
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
MXPA03008837A (es) Una composicion farmaceutica estable de pravastatina.
MXPA01004457A (es) Derivados pirimidina novedosos y procesos para la preparacion de los mismos.
BG106151A (en) Pharmaceutical complex
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
MY118175A (en) Crystalline pharmaceutical product
DE60029979D1 (de) LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT
BG106236A (en) Melt granulation
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS
SE9902674D0 (sv) New composition